AllSci News
Aura Biosciences raises USD 260.3m in public offering of common stock
Aura Biosciences (Nasdaq: AURA) announced the pricing of an underwritten public offering to fund registration-enabling activities for its lead asset,...
Ovarian Cancer Canada hands USD 725k to natural killer cell immunotherapy program at Dalhousie University
Ovarian Cancer Canada has announced USD 725,000 in ovarian cancer treatment funding for a natural killer (NK) cell immunotherapy program led by Dr. Jeanette...
Oncolytics' pelareorep shows durable responses in second-line KRAS-mutant colorectal cancer
Oncolytics Biotech (Nasdaq: ONCY) reported a median duration of response of 19.5 months for pelareorep in combination with bevacizumab and FOLFIRI in...
Atsena's Atsn-201 achieves foveal schisis closure in X-linked retinoschisis Phase I/II/III trial
Atsena Therapeutics reported interim six-month data from Part B of the Phase I/II/III LIGHTHOUSE trial evaluating ATSN-201 in X-linked retinoschisis,...
Atossa Therapeutics wins FDA Rare Pediatric Disease designation for Z-endoxifen in McCune-Albright Syndrome
Atossa Therapeutics (Nasdaq: ATOS) announced receipt of an FDA Rare Pediatric Disease (RPD) designation for (Z)-endoxifen in the treatment of McCune-Albright Syndrome…
Oruka Therapeutics raises USD 700.4m in underwritten public offering
Menlo Park, California-based Oruka Therapeutics, Inc. (Nasdaq: ORKA) announced the pricing of an upsized underwritten public offering on April 28, 2026,...
Windward Bio closes USD 165m financing for long-acting immunology therapies
Basel-based Windward Bio has closed a USD 165 million crossover financing round to advance its pipeline of long-acting antibody therapies targeting serious...
BioCryst grants Neopharmed Gentili European rights to navenibart for hereditary angioedema, USD 345m deal
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary...
Gyre Therapeutics completes USD 300m acquisition of Cullgen to create integrated US-China biotech company
Gyre Therapeutics (Nasdaq: GYRE) has completed the acquisition of Cullgen Inc., a privately held, clinical-stage biopharmaceutical company focused on...
FDA approves ADMA Biologics’ Asceniv for pediatric immune compromised patients aged two and older
ADMA Biologics announced US FDA approval of a supplemental Biologics License Application for Asceniv (immune globulin intravenous, human – slra 10% liquid),…
Latus Bio closes USD 97m Series A financing for AAV gene therapy pipeline
Philadelphia-based Latus Bio has closed a USD 97 million Series A financing round to advance its AAV gene therapy pipeline, with lead programs targeting...
National Pediatric Cancer Foundation awards USD 1m grant to Children's Hospital Los Angeles for rhabdomyosarcoma research
The National Pediatric Cancer Foundation has awarded a USD 1 million pediatric cancer research grant to JinSeok Park, PhD, at Children's Hospital Los...
Takeda's Tak-881 meets primary endpoint in Phase II/III primary immunodeficiency disease trial
Takeda (TSE:4502/NYSE:TAK) reported that TAK-881, an investigational immune globulin subcutaneous 20% formulation facilitated by recombinant human...
FDA approves Guardant360 CDx companion diagnostic for Arvinas and Pfizer's Veppanu in advanced breast cancer
The US FDA has approved Guardant360 CDx as a companion diagnostic for Veppanu (vepdegestrant), the PROTAC estrogen receptor degrader jointly developed by...
Clene planning NDA filing for CNM-Au8 gold nanocrystal suspension for ALS
Clene Inc. announced plans to file a New Drug Application (NDA) with the US FDA for CNM-Au8, an oral suspension of gold nanocrystals, seeking accelerated...
The AllSci Brief
Free, systematic R&D and deal news. Daily.